Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
Nalam, M.N., Ali, A., Reddy, G.S., Cao, H., Anjum, S.G., Altman, M.D., Yilmaz, N.K., Tidor, B., Rana, T.M., Schiffer, C.A.(2013) Chem Biol 20: 1116-1124
- PubMed: 24012370 
- DOI: 10.1016/j.chembiol.2013.07.014
- Primary Citation of Related Structures:  
3O99, 3O9A, 3O9B, 3O9C, 3O9D, 3O9E, 3O9F, 3O9G, 3O9H, 3O9I - PubMed Abstract: 
The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhibitors within the consensus volume of natural substrates, providing inhibitors less susceptible to resistance because a mutation affecting such inhibitors will simultaneously affect viral substrate processing ...